Rajesh K. Rajpal, MD

Clinicians discuss how the treatment compares with epi-off cross-linking, what may shape adoption, and how patient outcomes could improve.

Rajpal shares his perspectives on the newly FDA-approved treatment, clinical benefits, and its potential impact on keratoconus management.